iifl-logo-icon 1

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

sidebar image

AstraZeneca India Posts 31% Revenue Surge in Q2

14 Nov 2024 , 10:48 AM

AstraZeneca Pharma India reported its financial results for Q2 FY25, showing a notable revenue increase.

Revenue from operations surged by 31% to ₹408 Crore in Q2, compared to the same period last year. For the first half (H1) of FY25, the revenue rose to ₹795.5 Crore, driven by growth in oncology, biopharmaceuticals, and rare disease segments. Profit before exceptional items and tax for Q2 stood at ₹51 Crore, with a profit after tax of ₹38.4 Crore, recovering from a net loss of ₹11.8 Crore in Q1.

CFO Bhavana Agrawal highlighted the company’s steady growth in India, attributing it to consistent progress in oncology, biopharmaceuticals, and rare diseases. Country President and Managing Director Dr. Sanjeev Panchal emphasized AstraZeneca’s commitment to healthcare innovation in India, focusing on expanding access to advanced therapies and strengthening healthcare systems.

AstraZeneca introduced two new products, palivizumab and tremelimumab injections, into the Indian market, receiving regulatory approval from the Drugs Controller General of India (DCGI).

The company’s “Growth Through Innovation” strategy is aimed at meeting unmet patient needs in India, underscoring a commitment to science-driven healthcare solutions.

Related Tags

  • AstraZeneca
  • AstraZeneca news
  • Astrazeneca Pharma
  • Pharma
  • Pharma news
  • Q2 profit news
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Center
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Capital Services Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Loading...

Follow us on

facebooktwitterrssyoutubeinstagramlinkedintelegram

2024, IIFL Capital Services Ltd. All Rights Reserved

ATTENTION INVESTORS

RISK DISCLOSURE ON DERIVATIVES

Copyright © IIFL Capital Services Limited (Formerly known as IIFL Securities Ltd). All rights Reserved.

IIFL Securities Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp